Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: a phase II study.

[1]  M. van Glabbeke,et al.  High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary Group. , 1995, European journal of cancer.

[2]  D. Jodrell,et al.  Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  B. Redman,et al.  Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Fosså,et al.  Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the European Organization for Research and Treatment of Cancer, genitourinary group prospective randomized phase III study (30865). , 1993, The Journal of urology.

[5]  B. Dahllöf,et al.  Estramustine depolymerizes microtubules by binding to tubulin. , 1993, Cancer research.

[6]  S. Mondillo,et al.  Weekly chemotherapy in advanced prostatic cancer. , 1993, British Journal of Cancer.

[7]  M Mazumdar,et al.  Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Yagoda,et al.  Cytotoxic chemotherapy for advanced hormone‐resistant prostate cancer , 1993, Cancer.

[9]  K. Tew,et al.  Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  E. Paus,et al.  The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer. , 1992, British Journal of Cancer.

[11]  S. Fosså,et al.  Prognostic factors in hormone-resistant progressing cancer of the prostate. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  T. Hedner,et al.  Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors. , 1992, BMJ.

[13]  M. Gleave,et al.  Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. , 1992, Cancer research.

[14]  H. Scher,et al.  Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. , 1992, The Journal of urology.

[15]  S. Fosså,et al.  Prostate-specific antigen and other prognostic factors in patients with hormone-resistant prostatic cancer undergoing experimental treatment. , 1992, British journal of urology.

[16]  W. Linehan,et al.  Effect of suramin on human prostate cancer cells in vitro. , 1991, The Journal of urology.

[17]  K. Tew,et al.  Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells , 1988, The Journal of cell biology.

[18]  K. Fokas,et al.  Comparative experimental study of the serum prostate specific antigen and prostatic acid phosphatase in serially transplantable human prostatic carcinoma lines in nude mice. , 1988, The Journal of urology.

[19]  J. Klijn,et al.  European Organization for Research and Treatment of Cancer (EORTC) phase II study of low-dose weekly epirubicin in metastatic prostate cancer. , 1987, Cancer treatment reports.

[20]  R. Sylvester,et al.  Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. , 1986, The Journal of urology.

[21]  R. Sylvester,et al.  A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: final analysis of a phase III trial of the European Organization for Research on Treatment of Cancer. , 1986, The Journal of urology.

[22]  R. Benson,et al.  Estramustine Phosphate Compared with Diethylstilbestrol A Randomized, Double‐Blind, Crossover Trial for Stage D Prostate Cancer , 1986, American journal of clinical oncology.

[23]  R. Wittes,et al.  A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  F. Ganzina.  4'-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. , 1983, Cancer treatment reviews.

[25]  E. Paus,et al.  Reduction of serum prostate-specific antigen during endocrine or cytotoxic treatment of hormone-resistant cancer of the prostate. A preliminary report. , 1994, European urology.

[26]  S. Fosså,et al.  Prediction of pelvic lymph node metastases by a prostate-specific antigen and prostatic acid phosphatase in clinical T3/T4M0 prostatic cancer. , 1992, European urology.

[27]  B. Hartley‐åsp,et al.  Mechanisms of action and clinical uses of estramustine. , 1990, Cancer investigation.

[28]  S. Fosså,et al.  Quality of life and treatment of hormone resistant metastatic prostatic cancer. The EORTC Genito-Urinary Group. , 1990, European journal of cancer.

[29]  F. Pannuti,et al.  High-dose epirubicin for untreated patients with advanced tumours: a phase I study. , 1990, European journal of cancer.

[30]  S. Fosså,et al.  Quality of life and treatment of hormone resistant metastatic prostatic cancer , 1990 .

[31]  M. Soloway,et al.  Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan , 1988, Cancer.

[32]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.